<DOC>
	<DOC>NCT01430546</DOC>
	<brief_summary>The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.</brief_summary>
	<brief_title>Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>1. Be at least 18 years of age 2. Have a confirmed diagnosis of MM 3. Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after one prior treatment. 4. Have personally signed and dated a legally effective written informed consent form prior to admission to the study. 5. Must be willing and able to understand and comply with the study requirements. 1. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening. 2. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Relapsed and Refractory Multiple Myeloma</keyword>
</DOC>